This morning, FibroGen announced topline data from the Phase 3 LELANTOS-1 study of pamrevlumab, their investigational monoclonal antibody, for non-ambulatory patients with Duchenne muscular dystrophy.
Although generally safe and well tolerated, pamrevlumab did not meet the primary endpoint of Performance of the Upper Limb 2.0 (PUL 2.0) score at week 52 compared to baseline.
PPMD has reached out to FibroGen to learn more about next steps for the study and what is next for the participating patients. While we are disappointed to hear the study did not reach its primary endpoint, we look forward to learning more from FibroGen about the path forward for pamrevlumab in non-ambulatory boys with Duchenne.
The LELANTOS-2 ambulatory study is ongoing and a topline data read out is planned for Q3 2023.
FibroGen will be participating in PPMD’s Annual Conference in Dallas, Texas on Friday, June 30 during the Research Row: Impacting Downstream sessions. Click here for more information on PPMD’s Annual Conference and registration.